Eugene L. Palatulan
<p>The clinical focus is treating musculoskeletal injuries of people ages 13 and up, from weekend warriors to high-level athletes, those who are trying to remain active, and those who need help getting active. Particular interest in ultrasound-guided interventions and other available interventions for musculoskeletal joint pain.</p>
<p>Clinical research in musculoskeletal ultrasound. </p>
<p>Eugene Palatulan, MD, MA, is a sports medicine attending physician and Assistant Professor at Montefiore Einstein. Dr. Palatulan’s clinical focus is in treating musculoskeletal injuries of adolescents and adults of all levels of fitness and ability. He has particular interest in ultrasound-guided interventions and other available interventions for the treatment of musculoskeletal joint and tendinopathy pain.</p><p>After earning his Bachelor of Arts from Swarthmore College in 2005 and his Master of Arts at Columbia University in 2006, Dr. Palatulan spent several years in education, teaching high school biology in Bronx public high schools. He then pursued his medical education, first completing his post-baccalaureate with State University of New York at Buffalo in 2013, then pursuing his Doctor of Medicine at Albert Einstein College of Medicine at Yeshiva University, earning his medical degree in 2017. He completed his physical medicine and rehabilitation residency at NewYork-Presbyterian–Columbia/Cornell in 2021, and his sports medicine fellowship at the Hospital of the University of Pennsylvania in 2022. Throughout his career, he has enjoyed taking a holistic approach in the care of athletes and patients of all ages and abilities. He has been a team physician for a multitude of teams of all levels. He has worked as team physician for UPENN Football, Sprint Football, Men's and Women's Lacrosse, Men's and Women's Soccer and Men's and Women's basketball teams during his fellowship at PENN Sports Medicine. He worked closely and alongside head team physicians for the Philadelphia Eagles and Philadelphia Flyers in taking care of elite professional football and hockey players and was a critical team member in getting their pre-participation physicals completed. He was part of the team who took care of the Team USA Women's soccer team during their exhibition match in Philadelphia in 2022. He enjoys covering track and field and was assistant Chief Medical Officer for the annual PENN relays and worked as track captain throughout the event. The experience served him immensely as the covering medical director for the MAAC indoor Track and Field championships at the Nike Armory Indoor Track. Dr. Palatulan also enjoys mass coverage such as marathons and he has worked as a race captain for Broad Street Run and Philadelphia Love Marathon during sports fellowship year as well as the NYC Marathon going back to his years as a medical student (2013-2017), residency years (2018-2021) and he plans to keep on volunteering as an attending physician overlooking care and injury prevention in various medical tents along the marathon. He currently directs the Montefiore Einstein Adaptive Sports program serving a vast population in the Bronx and beyond of adaptive athletes and participants. He currently enjoys being a team physician for professional athletes, local high schools and colleges, including taking care of the New York City FC II in MLS Next Pro league team. He has been vetted as part of the network of USA Soccer Federation (USSF) Preferred Provider and is proud to have taken care of US Soccer athletes and elite soccer athletes. He is also excited to be a team physician and be part of the Cool Runnings journey with the Jamaica Bobsleigh Team.</p><p>Dr. Palatulan’s clinical research focuses on musculoskeletal ultrasound and care and management of athlete injuries and access to sports medicine particularly with pre-participation physicals/screening in high school and collegiate levels. He also takes a strong interest in injury prevention and delves into research on relative energy deficiency in sports (RED-S) and overuse injuries leading to tendinopathy and soft tissue injuries. His work has been shared through peer-reviewed journals, posters and abstracts.</p><p>Dr. Palatulan is a member of several professional organizations including the American Medical Society for Sports Medicine, the New York Society of Physical Medicine and Rehabilitation, the American Academy of Physical Medicine and Rehabilitation, and the Association of Academic Physiatrists.</p>
Mauricio Drummond, Jr.
Dr. Drummond’s clinical focus is in pediatric sports medicine with a special focus on knee pathology.
Dr. Drummond’s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears
<p>Mauricio Drummond Jr., MD, is an attending surgeon and Assistant Professor, Pediatrics and Orthopedic Surgery at Children’s Hospital at Montefiore. Dr. Drummond’s clinical focus is in pediatric sports medicine with a special focus on knee pathology. His interests include pediatric orthopedic surgery, complex pediatric and adolescent sports medicine, ACL, PCL and multiligament knee injuries, discoid meniscus, meniscus transplantation, patellofemoral instability, trochlear dysplasia, cartilage preservation and pediatric trauma and limb deformities.</p><p>In 1996, Dr. Drummond earned his Doctor of Medicine from Universidade Federal do Rio de Janeiro (Federal University of Rio de Janeiro) in Rio de Janeiro, Brazil. He completed his residency training at the same institution, and practiced as a knee specialist for more than 13 years in Brazil. In 2018, he came to the United States, completing an orthopedic surgery research fellowship at Cleveland Clinic Foundation in 2019 and an orthopedic sports medicine fellowship at the University of Pittsburgh Medical Center in 2020. He continued his postdoctoral training, completing his pediatric orthopedics and limb deformity fellowship at Montefiore Medical Center in 2021 and his pediatric orthopedics fellowship at Connecticut Children’s Medical Center in 2022.</p><p>Dr. Drummond’s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears. He has shared his work nationally and internationally through peer-reviewed journals and podium and poster presentations. He is also a reviewer for the <em>American Journal of Sports Medicine</em>.</p><p>Dr. Drummond is a member of several professional organizations including the International Society of Arthroscopy and Knee Orthopaedic Sports Medicine (ISAKOS), the American Orthopaedic Society for Sports Medicine (AOSSM), the Pediatric Orthopaedic Society of North America (POSNA) and the Pediatric Research in Sports Medicine Society (PRiSM).</p>
Shiu M. Young
Rui Yang
<p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopaedic residency at Peking University People’s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a Master’s degree in Biological Sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopaedic surgery residency at the University of Texas, in Houston and then he did a fellowship in Orthopaedic Oncology at Memorial Sloan-Kettering Cancer Center.</p>
<p>Dr. Yang specializes in the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system. A multidisciplinary approach is emphasized in his practice. He performs surgery to remove the tumor fom the limb and pelvis, and rebuild them using techniques tailored for each individual patient. Dr. Yang is also interested in treating metastatic bony lesions originating from other parts of the body.</p>
<p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumorigenesis of osteosarcoma and the genetic profile of the tumors as comparison to its normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, as well as novel strategies to overcome it in collaboration with the pediatric sarcoma teams.</p>
<p> </p>
Diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors.<quillbot-extension-portal></quillbot-extension-portal>
Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.<quillbot-extension-portal></quillbot-extension-portal>
<p>1. Peer-reviewed Papers</p>
<p>1) <strong>Yang, R.</strong>, Piperdi, S., Zhang, Y., Neophytou, N., Zhu, W., Hoang, B.H., Mason, G., Geller, D., Dorfman, H,, Healey, J.H., Phinney, D.G., and Gorlick, R. Transcriptional Profiling Identifies the Signaling Axes of the Insulin Growth Factor and the Transforming Growth Factor-beta as involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res. 2015. PMID: 26463566</p>
<p>2) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.,</strong> Linkov, I., Sowers, R., DiResta, G.R., Gorlick, R., Healey, J.H. Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma <a href="http://www.ncbi.nlm.nih.gov/pubmed/20052438">.</a> Ann Acad Med Singapore. 2009; 38(12):1041-7. PMID: 20052438</p>
<p>3) Li, N., <strong>Yang, R.</strong>, Zhang, W., Dorfman, H., Rao, P., and Gorlick, R. Genetically Transforming Human Mesenchymal Stem Cells to Sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer. 2009; 115(20): 4795-806. PMID: 19593798</p>
<p>4) <strong>Yang, R</strong>., Piperdi, S., and Gorlick, R. Activation of the RAF/MEK/ERK pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res. 2008;14(20): 6396-404. PMID: 18927278</p>
<p>5) <strong>Yang, R.</strong>, Qin, J., Hoang, B.H., Healey, J.H., and Gorlick, R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 2008;466:2046-51. PMID: 18528741</p>
<p>6) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.</strong>, Linkov, I., Sowers, R., Diresta, G.R., Gorlick, R., and Healey, J.H. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 2008;26:1-6. PMID: 18473395</p>
<p>7) <strong>Yang, R.</strong>, Li, W.W., Hoang, B.H., Kim, H., Banerjee, D., Kheradpour, A., Healey, J.H., Meyers, P.A., Bertino, J.R., and Gorlick, R. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008;8:124. PMID: 18452618</p>
<p>8) <strong>Yang, R.</strong>, Kolb, E.A., Qin, J., Chou, A., Sowers, R., Hoang, B., Healey, J.H., Huvos, A.G., Meyers, P.A. and Gorlick, R. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007;13:2557-67. PMID: 17473184</p>
<p>9) <strong>Yang, R.</strong>, Hoang, B.H., Kubo, T., Kawano, H., Chou, A., Sowers, R., Huvos, A.G., Meyers, P.A., Healey, J.H. and Gorlick, R. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007;121:943-54. PMID: 17410535</p>
<p>10) Laverdiere, C., Hoang, B.H., <strong>Yang, R.</strong>, Sowers, R., Qin, J., Meyers, P.A., Huvos, A.G., Healey, J.H. and Gorlick, R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-7. PMID: 15814634</p>
<p>11) Nathan, S.S., DiResta, G.R., Casas-Ganem, J.E., Hoang, B.H., Sowers, R., <strong>Yang, R.</strong>, Huvos, A.G., Gorlick, R. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005;11:2389-97. PMID: 15788690</p>
<p>12) Flintoff, W.F., Sadlish, H., Gorlick, R., <strong>Yang, R.</strong>, Williams, F.M. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 2004;1690:110-7. PMID: 15469899</p>
<p>13) Hoang, B.H., Kubo, T., Healey, J.H., <strong>Yang, R.</strong>, Nathan, S.S., Kolb, E.A., Mazza, B., Meyers, P.A. and Gorlick, R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64:2734-9. PMID: 15087387</p>
<p>14) Hoang, B.H., Kubo, T., Healey, J.H., Sowers, R., Mazza, B., <strong>Yang, R.</strong>, Huvos, A.G., Meyers, P.A. and Gorlick, R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106-11. PMID: 14735475</p>
<p>15) <strong>Yang, R.</strong>, Sowers, R., Mazza, B., Healey, J.H., Huvos, A., Grier, H., Bernstein, M., Beardsley, G.P., Krailo, M.D., Devidas, M., Bertino, J.R., Meyers, P.A. and Gorlick, R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003;9:837-44. PMID: 12576457</p>
<p> </p>
<p>2. Book Chapters</p>
<p align="left">1) Orthopedic Oncology. Editor: Xun, W.P., Feng, C.H. People’s Military Medical Publisher.</p>
<p>(ISBN: 7-80157-159-2), 2001.</p>
<p>2) Review of Surgery: A Guiding Book for Medical Students. Section of Orthopedics. Editor: Jiang, B.G. Beijing Medical University Publisher. (ISBN: 7-81034-946-5), 1999.</p>
<p>Dr. Yang is a fellowship-trained orthopedic surgeon recognized for his multidisciplinary approach to the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors. He also serves as an Assistant Professor at our Albert Einstein College of Medicine.</p><p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopedic residency at Peking University People?s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a master?s degree in biological sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopedic surgery residency at the University of Texas, in Houston, followed by a fellowship in orthopedic oncology at Memorial Sloan-Kettering Cancer Center.</p><p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.</p>
Mitchell C. Weiser
Treating conditions of the hip and knee, including osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, and osteonecrosis. <quillbot-extension-portal></quillbot-extension-portal>
Dr. Weiser's current research interests focus on post-operative pain management, surgical outcomes, infection, and airflow patterns in the operating room.<quillbot-extension-portal></quillbot-extension-portal>
<p>Mitchell Weiser, MD, is Director, Adult Reconstruction Joint Replacement Fellowship Program at Montefiore Einstein and Assistant Professor, Orthopedic Surgery at our Albert Einstein College of Medicine. He specializes in treating conditions of the hip and knee, including osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, and osteonecrosis. Dr. Weiser helps patients evaluate their surgical and non-surgical options, and helps them choose the most minimally invasive treatment whenever possible. When surgery is needed, he is skilled at performing both conventional and computer-navigated primary and revision (re-do) hip and knee replacements.</p><p>After completing two undergraduate engineering degrees from Rensselaer Polytechnic Institute, Dr. Weiser attended Cornell University, earning his Masters of Engineering. He earned his medical degree from the State University of New York at Stony Brook, and completed his residency in orthopedic surgery at the Icahn School of Medicine at Mount Sinai. He then completed an extra year of specialty fellowship training in joint replacement surgery at NYU Langone Medical Center and the Insall Scott Kelly Institute of Orthopedics and Sports Medicine.</p><p>Dr. Weiser’s research interests focus on post-operative pain management, surgical outcomes, infection and airflow patterns in the operating room. He has published numerous research articles in the <em>Journal of Bone and Joint Surgery, The Journal of Arthroplasty, Arthroplasty Today</em>, and the <em>Journal of American Association of Orthopedic Surgeons</em>. He has presented his research at national meetings including the annual meetings of the American Association of Orthopedic Surgeons, the Orthopedic Research Society, and the American Association of Hip and Knee Surgeons. He also serves as an academic journal reviewer for numerous medical journals including the <em>Journal of Arthroplasty, British Journal of Anaesthesia, Journal of Hip Surgery</em> and BMC Surgery.</p><p>Dr. Weiser is board certified, a Diplomate of the American Board of Orthopaedic Surgery and a member of the American Academy of Orthopedic Surgeons and the American Association of Hip and Knee Surgeons. He volunteers his time and expertise on a national level, serving as a committee member of the American Academy of Orthopedic Surgeons.</p>
Daniel A. Weiser
<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials. </p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children’s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. – Stony Brook University, NY</li>
<li>Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship – The Children’s Hospital of Philadelphia, PA</li>
</ul>
DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.
<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia. </p><p>Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>
Stanley F. Wainapel
<p>My primary areas of clinical and research interest are: Complementary/Alternative Medicine (CAM); physical disability among physicians and medical students; medical problems in musicians; ethical aspects of rehabilitation research; and disability in the novels of Charles Dickens. My long-term research goal is to write a book on Dickens and Medicine. </p>
<span class="TextRun SCXW33707701 BCX8" data-contrast="none" lang="EN-US" style="white-space:pre-wrap;margin:0px;padding:0px;user-select:text;-webkit-user-drag:none;-webkit-tap-highlight-color:transparent;font-size:11pt;line-height:16px;font-family:Arial, Arial_EmbeddedFont, Arial_MSFontService, sans-serif;font-variant-ligatures:none !important;" xml:lang="EN-US">Dr. Wainapel has a wide range of clinical interests including geriatric rehabilitation, complementary/alternative therapies for pain management, vision rehabilitation, and performing arts medicine</span><span class="EOP SCXW33707701 BCX8" data-ccp-props="{"201341983":0,"335559739":0,"335559740":240}" style="white-space:pre-wrap;margin:0px;padding:0px;user-select:text;-webkit-user-drag:none;-webkit-tap-highlight-color:transparent;font-size:11pt;line-height:16px;font-family:Arial, Arial_EmbeddedFont, Arial_MSFontService, sans-serif;"> </span>
<span class="TextRun SCXW12926019 BCX8" data-contrast="none" lang="EN-US" style="margin:0px;padding:0px;user-select:text;-webkit-user-drag:none;-webkit-tap-highlight-color:transparent;white-space:pre-wrap;background-color:#ffffff;font-size:11pt;line-height:16px;font-family:Arial, Arial_EmbeddedFont, Arial_MSFontService, sans-serif;font-variant-ligatures:none !important;" xml:lang="EN-US"><span class="NormalTextRun SCXW12926019 BCX8" style="margin:0px;padding:0px;user-select:text;-webkit-user-drag:none;-webkit-tap-highlight-color:transparent;"></span></span>Vision rehabilitation, the history of Physical Medicine and Rehabilitation, physical disabilities among physicians, and bioethics are the main focuses of Dr. Wainapel’s research.<span 201341983":0,"335559739":0,"335559740":240}"="" class="EOP SCXW12926019 BCX8" data-ccp-props="{" style="margin:0px;padding:0px;user-select:text;-webkit-user-drag:none;-webkit-tap-highlight-color:transparent;white-space:pre-wrap;background-color:#ffffff;font-size:11pt;line-height:16px;font-family:Arial, Arial_EmbeddedFont, Arial_MSFontService, sans-serif;"></span><quillbot-extension-portal></quillbot-extension-portal>
<p>Stanley F. Wainapel, MD, MPH, is Clinical Director, Physical Medicine and Rehabilitation at Montefiore, and Professor of Clinical Physical Medicine and Rehabilitation at our Albert Einstein College of Medicine. Since joining the Montefiore team, his clinical focus has been general rehabilitation, vision rehabilitation, chronic pain, and acupuncture.</p><p>In 1970, Dr. Wainapel received his Bachelor of Arts after completing a 6-year medical program at Boston University. During this time, he also attended Boston University School of Medicine, where he received his Doctor of Medicine in 1970. He began his postgraduate training in 1970 with a year-long internship in medicine at Genessee Hospital, followed by a residency at Albert Einstein College of Medicine, which he completed in 1974. In 1982, Dr. Wainapel his Master of Public Health in 1989 from Boston University.</p><p>Vision rehabilitation, the history of Physical Medicine and Rehabilitation, physical disabilities among physicians, and bioethics are the main focuses of Dr. Wainapel’s research. His work has been presented nationally at many guest lectures and published in numerous books and textbooks.</p><p>From 1982 to 1985, Dr. Wainapel was President of the American Society of Handicapped Physicians. He also spent a year as President of the New York Society of Physical Medicine and Rehabilitation in 1991. Dr. Wainapel is a diplomat of the National Board of Medical Examiners and the American Board of Physical Medicine and Rehabilitation.</p>
Sayed E. Wahezi
<p>Dr. Wahezi earned his medical degree from the School of Medicine and Biomedical Sciences at Buffalo and completed his Residency in Physical Medicine and Rehabilitation at Montefiore Medical Center, where he served as Chief Resident. He then completed an Interventional Spine fellowship at Spine Technology and Rehabilitation under the mentorship of Joseph D. Fortin. Following his training he completed a Pain Medicine Fellowship at Montefiore Medical Center, where he cultivated the clinical and academic development of the Pain Program.</p>
<p>Dr. Wahezi currently serves as Associate Professor of PMR and Anesthesiology at Montefiore Medical Center in New York City where he serves as the Program Director of the ACGME accredited Pain Fellowship. He has created a fellowship with an interventional focus and multidisciplinary foundation. His mission is to create an academic environment which fosters the growth of Pain Medicine by education and investigation/development of new devices and techniques.</p>
<p>Dr. Wahezi is a long-standing member of the American Society of Interventional Pain Physicians (ASIPP), American Academy of Pain Medicine (AAPM), New York Pain Society (NYPS), Association of Academic Physiatrists, New York Pain Society (NYPS), and Eastern Pain Association. He is a nominated AAPMR delegate representative for the American Medical Association’s (AMA) Expert Panel on Pain Management, nominated representative on ASIPP’s expert lumbar stenosis panel and the Board of Directors for the NYPS. He is a graduate of the Academy of Academic Physiatrists’ (AAP) Program for Academic Leadership (PAL), nominated Board of Director member for the Academy of Pain Program Directors (APPD), Reviewer and Editor for the <em>Pain Physician Journal</em>, co-director of for American Academy of Pain Medicine (AAPM) membership council. He is also a nominated member of the Promotions Committee at Montefiore/Einstein. In addition, he is a nominated <em>Super Doctor</em>, as identified by the New York Times Magazine.</p>
<p>Dr. Wahezi has authored more than fifty publications in peer reviewed pain journals, book chapters, abstracts, and posters. He has presented several lectures at national meetings, and has given more than 150 academic lectures in Pain Management. He is actively involved in basic science and clinical studies in Pain management. His basic science interests include the physiology of neuropathic and orthopedic pain. His clinical research interests include innovative percutaneous pain treatments.</p>
Dr. Wahezi’s clinical focus is in interventional pain medicine.<quillbot-extension-portal></quillbot-extension-portal>
Dr. Wahezi’s research interests include innovative percutaneous pain treatments and his basic science interests include the physiology of neuropathic and orthopedic pain. He is actively involved in basic science and clinical studies in pain management. <quillbot-extension-portal></quillbot-extension-portal>
<p>Sayed Emal Wahezi, MD, is Professor and Program Director of the Pain Medicine Fellowship at Montefiore Einstein. Dr. Wahezi’s clinical focus is in interventional pain medicine.</p><p>A graduate of State University of New York at Buffalo, Dr. Wahezi earned his Doctor of Medicine in 2005. He completed his internal medicine internship at Cornell University, New York Hospital, Queens in 2006, then came to Montefiore to complete his residency in physical medicine and rehabilitation in 2009, serving as chief resident in his final year. In 2010, Dr. Wahezi completed his interventional spine and musculoskeletal fellowship at Spine Technology and Rehabilitation, then returned to Montefiore to complete a pain medicine fellowship in 2013, and created the clinical and academic foundation for Pain Medicine at Montefiore.</p><p>Dr. Wahezi’s research interests include innovative percutaneous pain treatments and his basic science interests include the physiology of neuropathic and orthopedic pain. He is actively involved in basic science and clinical studies in pain management. Dr. Wahezi has authored more than 80 publications in peer-reviewed pain journals, book chapters, abstracts and posters. Many of Dr. Wahezi’s publications have led to the innovation of novel interventional pain procedures. He has given more than 200 academic lectures in pain management across the country. He is a reviewer and editor for several pain journals.</p><p>Dr. Wahezi is certified by the American Board of Physical Medicine and Rehabilitation. He is a long-standing member of the American Society of Interventional Pain Physicians (ASIPP), American Academy of Pain Medicine, New York Pain Society (NYPS), Association of Academic Physiatrists (AAP), Eastern Pain Association (EPA) and Association of Pain Program Directors (APPD). He is a nominated American Academy of Physical Medicine and Rehabilitation (AAPMR) delegate representative for the American Medical Association’s Expert Panel on Pain Management, nominated representative on ASIPP’s expert lumbar stenosis panel and the Board of Directors for the NYPS. He is also a graduate of the AAP Program for Academic Leadership (PAL) and a past president of the APPD. He serves on the Board of Directors for American Society of Regional Anesthesia and Pain Medicine (ASRA), is a member of the Educational Council for the Association of Pain and Neuroscience (ASPN), and is a co-director for the American Academy of Pain Medicine (AAPM) membership council.</p>